Assessment of drug-induced cardiotoxicity plays an important role in drug development. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have been widely used as a platform to evaluate cardiac toxicity/safety during drug development. Multi-electrode array (MEA) system with iPSC-CMs has been one of the standard assay systems to predict drug-induced proarrhythmic risk. In addition to MEA system, contractility is other key issues to prevent cardiotoxicity at later stages for drug development. Among various in vitro approaches, we focused on the electric cell-substrate impedance sensing system (ECIS) to monitor contractility. Although ECIS are expected for high-throughput screening, correlation between ECIS and contractility has not been fully elucidated. In the present study, we compared with waveform detected sequentially by ECIS and imaging-based cell motion system (CMI) using hiPSC-CMs (iCell CM, CDI). We found that several parameters, such as inflection point, beat rate, contraction rate, were correlated between ECIS and CMI. In addition, correlation with these parameters were confirmed in the treatment of isoproterenol and verapamil. These data suggest that contractility can be assessed by both impedance and imaging in iPSC-CMs. We are now planning to evaluate contractility using more compounds, such as anti-cancer agents, in iPSC-CMs.